AffyXell Therapeutics, the next-generation cell and gene therapy joint venture between Avacta and Daewoong, will develop a novel class of mesenchymal stem cell treatments that are engineered to also produce Affimer therapies in patients at a selected site of action.

Now, the collaboration will also include the development of therapies that repair lung damage caused by COVID-19 while also producing neutralizing Affimer molecules that prevent disease progression.

Avacta's Affimer reagent may neutralize SARS-CoV-2
Avacta Group, the developer of Affimer biotherapeutics and reagents, announced that several Affimer reagents block the interaction between SARS-CoV-2's...